Jagsonpal Pharmaceuticals Limited has announced a buyback of 16,00,000 fully paid-up equity shares at ₹250 per share, aggregating to ₹40,00,00,000. The Board of Directors approved the proposal on March 12, 2026, and shareholders approved it through postal ballot on April 24, 2026. The public announcement was published on April 29, 2026.

The buyback represents 2.39% of the total paid-up equity share capital and 18.35% of the aggregate of paid-up equity share capital and free reserves as of March 31, 2025. The offer will be executed through the tender offer route on a proportionate basis, with 15% of the shares reserved for small shareholders or the actual number of shares entitled to small shareholders based on their shareholding, whichever is higher.

Buyback Details

Key Provisions

The promoters and promoter group, holding 67.20% of the total equity shares, have confirmed they will not participate in the buyback. The buyback price of ₹250 per share represents a premium of approximately 39-48% over various market price benchmarks, including volume-weighted average prices and closing prices on BSE and NSE during periods preceding the intimation date.

The company has appointed Centrum Capital Limited as the Manager to the Buyback. A Buyback Committee has been constituted with Mr. Debasis Nandy, Mr. Manish Gupta, and Mr. Prithipal Singh Kochhar as members to oversee the implementation process. Mr. Pratham Rawal, Company Secretary, has been designated as the Compliance Officer for the buyback.

Financial Position and Funding

The funds for the buyback will be sourced from the company's free reserves, securities premium account, and internal accruals. The company confirms it is a debt-free entity with strong cash flows, having generated over ₹142 crores in free cash between FY22 and FY25. As of December 31, 2025, the company reported free cash of ₹176 crores, including ₹30 crore generated in Q3FY26.

The buyback is expected to improve return on equity by reducing the equity base and enhance earnings per share. The company estimates the transaction will lead to approximately 400 basis points improvement in Return on Capital Employed (ROCE). The buyback will be completed within 12 months from the date of passing the special resolution.

Jagsonpal Pharmaceuticals Limited has made the audio recording of its Q4 FY26 earnings conference call available on the company website. The jagsonpal pharmaceuticals informed both BSE and NSE about the availability of this recording following the completion of the scheduled investor engagement activity on April 28, 2026.

Conference Call Completion

The earnings conference call was successfully conducted as scheduled with the following details:

Audio Recording Availability

In continuation to the earlier intimation dated April 22, 2026, the company has announced that the complete audio recording of the Q4 FY26 earnings conference call is now accessible to stakeholders:

Regulatory Compliance

The company has notified stock exchanges about the audio recording availability pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Pratham Rawal digitally signed the official communication on April 28, 2026, at 17:54:14 +05'30'.

Investor Access

The audio recording provides comprehensive coverage of the Q4 FY26 financial results discussion that took place during the scheduled conference call. Investors, analysts, and other stakeholders who were unable to participate in the live session can now access the complete proceedings through the company's official website under the investor relations section.